摘要
由于缺乏理想的抗逆转录病毒措施,全球人类免疫缺陷病毒(HIV)的流行仍在蔓延。到目前为止,所有获得有效疫苗的尝试都以失败告终。高活性抗逆转录病毒疗法(HAART)是目前用于抑制HIV唯一有效的武器。然而,由于抗病毒药物耐药性的出现,HAART也有可能在不久的将来失去效果。本文揭示了传统治疗艾滋病毒和抗逆转录病毒方法失败的原因。考虑新抗逆转录病毒治疗策略的成功性经常被强调,目前的创新理念也需要考虑到这一点。受体诱饵陷阱(RDT)被称为抵消器,它是表达HIV从受体的表面进入受体细胞的红细胞,目前提出的理念倾向于利用这种抵消器。如果研制成功,该方法将以HIV自由颗粒为靶点,捕获的病毒并进行中和。本文将对这一概念转化为现实的可能途径,以及在这个过程中可能遇到的障碍进行讨论。另外,基于其成功的发展,我们还设想了抗HIV感染治疗和/或预防措施消除。
关键词: 抵消器,载体红细胞,功能性治愈,遗传操作,造血干细胞,HIV,受体诱饵陷阱。
图形摘要
Current Drug Targets
Title:Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
Volume: 17 Issue: 6
Author(s): Sundararaj Stanley Jeremiah, Kenji Ohba and Naoki Yamamoto
Affiliation:
关键词: 抵消器,载体红细胞,功能性治愈,遗传操作,造血干细胞,HIV,受体诱饵陷阱。
摘要: The global Human Immunodeficiency Virus (HIV) pandemic is still spreading due to the lack of ideal anti-retroviral measures and their availability. Till date, all attempts to produce an efficient vaccine have ended with unsatisfactory results. The highly active anti-retroviral therapy (HAART) is the only effective weapon currently available and is widely being used for curtailing the HIV pandemic. However, the HAART is also expected to fail in the near future due to the emergence and dissemination of antiviral resistance. This review sheds light on the reasons for the failure of the conventional anti-viral measures against HIV and the novel anti-retroviral strategies currently being developed. The various principles to be considered for the success of a novel anti-retroviral strategy are elaborately emphasized and an innovative concept is proposed on these lines. The proposed concept intends to use receptor decoy traps (RDT) called cancellers which are erythrocytes expressing the HIV entry receptors on their surface. If successfully developed, the cancellers would be capable of active targeting of the free HIV particles leading to the trapping of the viruses within the canceller, resulting in the neutralization of infectivity of the trapped virus. The possible ways of translating this concept into reality and the probable hurdles that can be encountered in the process are subsequently discussed. Also, the scope of cancellers in therapeutic and/or preventive strategies against HIV infection is envisaged upon their successful development.
Export Options
About this article
Cite this article as:
Sundararaj Stanley Jeremiah, Kenji Ohba and Naoki Yamamoto , Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/138945011706160324125824
DOI https://dx.doi.org/10.2174/138945011706160324125824 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy
Current Cancer Drug Targets Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics Recent Patents on the Identification and Clinical Application of microRNAs and Target Genes
Recent Patents on DNA & Gene Sequences Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs
Mini-Reviews in Medicinal Chemistry The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Function and Regulation of Let-7 Family microRNAs
MicroRNA Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Editorial: Stress and Gastrointestinal Tract: Physiology, Pathophysiology, Pathology and Pharmacology
Current Pharmaceutical Design Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued)